Gastroenterology
Volume 132, Issue 1 , Pages 52-65 , January 2007

Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial

  • Jean–Frédéric Colombel

      Affiliations

    • Department of Hepatogastroenterology, Hôpital Claude Huriez, Centre Hospitalier Universitaire de Lille, Lille, France
    • Jean-Frédéric Colombel, William Sandborn, Paul Rutgeerts, Robert Enns, Stephen Hanauer, Remo Panaccione, and Stefen Schreiber have served as consultants for Abbott Laboratories and have participated in continuing medical education events supported by unrestricted educational grants from Abbott Laboratories.
    • Corresponding Author InformationAddress requests for reprints to: Jean-Frédéric Colombel, MD, Hôpital Claude Huriez, Centre Hospitalier Universitaire de Lille, Rue Michel Polonovski, Lille, France 59037. fax: (33) 3-20-44-47-13.
    • ,
  • William J. Sandborn

      Affiliations

    • Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota
    • Jean-Frédéric Colombel, William Sandborn, Paul Rutgeerts, Robert Enns, Stephen Hanauer, Remo Panaccione, and Stefen Schreiber have served as consultants for Abbott Laboratories and have participated in continuing medical education events supported by unrestricted educational grants from Abbott Laboratories.
    • ,
  • Paul Rutgeerts

      Affiliations

    • Department of Gastro-Enterologie, University Hospital of Gasthuisberg, Leuven, Belgium
    • Jean-Frédéric Colombel, William Sandborn, Paul Rutgeerts, Robert Enns, Stephen Hanauer, Remo Panaccione, and Stefen Schreiber have served as consultants for Abbott Laboratories and have participated in continuing medical education events supported by unrestricted educational grants from Abbott Laboratories.
    • ,
  • Robert Enns

      Affiliations

    • Department of Medicine, St. Paul’s Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    • Jean-Frédéric Colombel, William Sandborn, Paul Rutgeerts, Robert Enns, Stephen Hanauer, Remo Panaccione, and Stefen Schreiber have served as consultants for Abbott Laboratories and have participated in continuing medical education events supported by unrestricted educational grants from Abbott Laboratories.
    • ,
  • Stephen B. Hanauer

      Affiliations

    • Section of Gastroenterology, University of Chicago, Chicago, Illinois
    • Jean-Frédéric Colombel, William Sandborn, Paul Rutgeerts, Robert Enns, Stephen Hanauer, Remo Panaccione, and Stefen Schreiber have served as consultants for Abbott Laboratories and have participated in continuing medical education events supported by unrestricted educational grants from Abbott Laboratories.
    • ,
  • Remo Panaccione

      Affiliations

    • Department of Medicine, Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, Alberta, Canada
    • Jean-Frédéric Colombel, William Sandborn, Paul Rutgeerts, Robert Enns, Stephen Hanauer, Remo Panaccione, and Stefen Schreiber have served as consultants for Abbott Laboratories and have participated in continuing medical education events supported by unrestricted educational grants from Abbott Laboratories.
    • ,
  • Stefan Schreiber

      Affiliations

    • Department of General Internal Medicine and Institute for Clinical Molecular Biology, Christian-Albrechts University, Kiel, Germany
    • Jean-Frédéric Colombel, William Sandborn, Paul Rutgeerts, Robert Enns, Stephen Hanauer, Remo Panaccione, and Stefen Schreiber have served as consultants for Abbott Laboratories and have participated in continuing medical education events supported by unrestricted educational grants from Abbott Laboratories.
    • ,
  • Dan Byczkowski

      Affiliations

    • Department of Immunology Development, Abbott Laboratories, Parsippany, New Jersey
    • Dan Byczkowski, Ju Li, Jeffrey Kent, and Paul Pollack are employees of Abbott Laboratories.
    • ,
  • Ju Li

      Affiliations

    • Department of Biostatistics and Data Management, Abbott Laboratories, Abbott Park, Illinois
    • Dan Byczkowski, Ju Li, Jeffrey Kent, and Paul Pollack are employees of Abbott Laboratories.
    • ,
  • Jeffrey D. Kent

      Affiliations

    • Department of Immunology Development, Abbott Laboratories, Parsippany, New Jersey
    • Dan Byczkowski, Ju Li, Jeffrey Kent, and Paul Pollack are employees of Abbott Laboratories.
    • ,
  • Paul F. Pollack

      Affiliations

    • Department of Immunology Development, Abbott Laboratories, Parsippany, New Jersey
    • Dan Byczkowski, Ju Li, Jeffrey Kent, and Paul Pollack are employees of Abbott Laboratories.

Received 11 August 2006 ,Accepted 28 September 2006.

References 

  1. Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology. 2000;119:1148–1157
  2. Van Deventer SJ. Tumour necrosis factor and Crohn’s disease. Gut. 1997;40:443–448
  3. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549
  4. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340:1398–1405
  5. Rutgeerts P, D’Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology. 1999;117:761–769
  6. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350:876–885
  7. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. N Engl J Med. 1997;337:1029–1035
  8. Baert F, Noman M, Vermeire S, Van Assche G, D’Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348:601–608
  9. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315–1324
  10. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology. 2003;124:917–924
  11. Hanauer S, Rutgeerts P, Targan S, Kam L, Present D, Mayer L, et al. Delayed hypersensitivity to infliximab (Remicade) re-infusion after a 2-4 year interval without treatment. (abstr) Gastroenterology. 1999;116:A731
  12. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol. 2004;2:542–553
  13. den Broeder A, van de Putte L, Rau R, Schattenkirchner M, Van Riel P, Sander O, et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol. 2002;29:2288–2298
  14. Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003;30:2563–2571
  15. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50:1400–1411
  16. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279–3289
  17. Rau R, Simianer S, van Riel PL, van de Putte LB, Kruger K, Schattenkirchner M, et al. Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate. Scand J Rheumatol. 2004;33:145–153
  18. van de Putte LB, Rau R, Breedveld FC, Kalden JR, Malaise MG, van Riel PL, et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis. 2003;62:1168–1177
  19. van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63:508–516
  20. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35–45
  21. Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003;25:1700–1702
  22. Haibel H, Rudwaleit M, Brandt HC, Grozdanovic Z, Listing J, Kupper H, et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis. Arthritis Rheum. 2006;54:678–681
  23. De Keyser F, Van den Bosch F, Mielants H. Anti-TNF-alpha therapy in ankylosis spondylitis. Cytokine. 2006;33:294–298
  24. Gordon KB, Bonish BK, Patel T, Leonardi CL, Nickoloff BJ. The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol. 2005;153:945–953
  25. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC I trial. Gastroenterology. 2006;130:323–333
  26. Sandborn WJ, Hanauer S, Enns R, Lukas M, Wolf D, Isaacs K, et al. Maintenance of remission over 1 year in patients with active Crohn’s disease treated with adalimumab: results of CLASSIC II, a blinded, placebo-controlled study (oral presentation OP-G-353). Gut. 2005;54(Suppl VII):A81–A82
  27. Sandborn WJ, Hanauer S, Lukas M, Wolf D, Isaacs K, MacIntosh D, et al. Clinical remission and response in patients with Crohn’s disease treated with open-label for 1 year with fully human anti-TNF-α monoclonal antibody adalimumab (oral presentation OP-G-78). Gut. 2005;54(Suppl VII):A18
  28. Barthel HR, Gille T, Halbsguth A, Kramer M. Successful treatment with adalimumab in infliximab-resistant Crohn’s disease. J Gastroenterol Hepatol. 2005;20:1464–1465
  29. Papadakis KA, Shaye OA, Vasiliauskas EA, Ippoliti A, Dubinsky MC, Birt J, et al. Safety and efficacy of adalimumab (D2E7) in Crohn’s disease patients with an attenuated response to infliximab. Am J Gastroenterol. 2005;100:75–79
  30. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, et al. Severe anaphylactic reaction to infliximab: successful treatment with adalimumab—report of a case. Eur J Gastroenterol Hepatol. 2004;16:627–630
  31. Sandborn WJ, Hanauer S, Loftus EV, Tremaine WJ, Kane S, Cohen R, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease. Am J Gastroenterol. 2004;99:1984–1989
  32. Stallmach A, Giese T, Schmidt C, Meuer SC, Zeuzem SS. Severe anaphylactic reaction to infliximab: successful treatment with adalimumab—report of a case. Eur J Gastroenterol Hepatol. 2004;16:627–630
  33. Youdim A, Vasikiauskas EA, Targan SR, Papadakis KA, Ippoliti A, Dubinsky MC, et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis. 2004;10:333–338
  34. Sandborn WJ, Rutgeerts P, Enns RA, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab rapidly induces clinical remission and response in patients with moderate to severe Crohn’s disease who had secondary failure to infliximab therapy: results of the GAIN Study. Ann J Gastroenterol. 2006;101(9 Suppl):S448
  35. Burmester G, Pangan A, Kent JD Lovell DJ, Gordon KB, Dijkmans BAC, Mease PH. Adalimumab is safe in global clinical trials in multiple indications and reduced mortality in rheumatoid arthritis (abstr). Ann Rheum Dis. 2006;65(Suppl II):181–182
  36. Schiff MH, Burmester GR, Kent JM, Pangan AL, Kupper H, Fitzpatrick SB, et al. Safety analysis of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:889–894

 Supported by a research grant from Abbott Laboratories (Abbott Park, IL).A list of the CHARM study investigators and sites appears in Appendix 1.

PII: S0016-5085(06)02522-4

doi: 10.1053/j.gastro.2006.11.041

Gastroenterology
Volume 132, Issue 1 , Pages 52-65 , January 2007

Article Tools

* Image Usage & Resolution